How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,190 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. GreenLight XPS for treating benign prostatic hyperplasia

GreenLight XPS for treating benign prostatic hyperplasia GreenLight XPS for treating benign GreenLight XPS for treating benign prostatic h prostatic hyperplasia yperplasia Medical technologies guidance Published: 14 June 2016 nice.org.uk/guidance/mtg29 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) for treating benign prostatic hyperplasia (MTG29) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 16 System impact 16 5 Cost considerations 18 Cost evidence 18 6 Conclusions 24 7 Committee members and NICE lead team 25 Medical

2016 National Institute for Health and Clinical Excellence - Medical technologies

102. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. (Full text)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. Although combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is one of the standard interventions in symptomatic benign prostatic hyperplasia (BPH), 5ARI monotherapy is seldom the focus of attention. Adverse events associated with 5ARI include depression and suicidal attempts in addition to persistent erectile dysfunction. The aim of this study (...) is to update our knowledge of clinical efficacy and incidence of adverse events associated with 5ARI treatment in symptomatic BPH.A meta-analysis of randomized controlled clinical trials (RCTs) from 1966 until March, 2017 was performed using database from PubMed, Cochrane Collaboration and Embase. A total of 23395 patients were included in this study and the inclusion criteria were: RCTs with 5ARI and placebo in symptomatic BPH patients. Parameters included prostate specific antigen (PSA), prostate volume

2018 PLoS ONE PubMed abstract

103. A prospective pilotstudy comparing the anesthetic effects of an alpha-2 agonist during holmium laser resection of the prostate and transurethral resection for prostate surgery for benign prostatic hyperplasia patients using selective alpha-1 blockers. (Full text)

A prospective pilotstudy comparing the anesthetic effects of an alpha-2 agonist during holmium laser resection of the prostate and transurethral resection for prostate surgery for benign prostatic hyperplasia patients using selective alpha-1 blockers. To examine the response to an α2receptor agonist used as a sedative for patients using long-term selective α1 blockers.Sixty-nine consecutive patients undergoing transurethral prostate resection or holmium laser resection of the prostateunder (...) loading dose injection of dexmedetomidine. Differencesbetween both groupswere noted at 15 min(group T: 100.2 ± 12.9 mmHg; group N: 90.0 ± 17.5 mmHg; P = 0.08), 20 min (group T: 99.8 ± 12.3 mmHg; group N: 87.4 ± 15.0 mmHg; P < 0.00), 25 min (group T: 99.3 ± 13.4 mmHg; group N: 85.4 ± 13.8 mmHg; P < 0.00), and 30 min (group T: 98.8 ± 13.1 mmHg; group N: 84.5 ± 13.5 mmHg; P < 0.00).The use of α2 agonists is appropriate during surgery for benign prostatic hyperplasia patients using tamsulosin

2018 BMC Anesthesiology PubMed abstract

104. Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia (Full text)

Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is a common urological disorder of men, characterized by prostatic enlargement and urethral obstruction. In this study, BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate (TP) for 3 weeks. Tetracarpidium conophorum was administered daily by oral (...) gavage at a dose of 100, 200 and 400 mg/kg BW of extract for three weeks, along with the TP injections and 5 mg/kg of finasteride for comparison. On day 21, the animals were sacrificed after anesthesia. Prostate were excised, weighed and used to determine relative prostate weight. Quantitative and qualitative phytochemical screening was also done and it showed the presence of flavonoids (0.370 mg/ml), tannins (0.458 mg/ml), phenols (0.508 mg/ml) and steroids (0.257 mg/ml). The prostate specific

2018 Data in brief PubMed abstract

105. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia (Full text)

Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia Background: Prostate cancer (PCa) represents the second most commonly diagnosed malignancy and the sixth leading cause for cancer related death among men worldwide. Although use of the prostate specific antigen (PSA) as a diagnostic marker has improved the detection and management of PCa, low specificity and sensitivity has limited its (...) clinical efficacy. Moreover, elevated PSA is frequently observed in benign prostate hyperplasia (BPH). Mean platelet volume (MPV) and platelet distribution width (PDW) are commonly used indicators of platelet activation. The purpose of current study was to investigate the ability of PSA, MPV, and PDW individually or in combination, to differentiate PCa from BPH. Materials and Methods: This study included 100 patients with PCa and 108 patients with BPH. We collected all participants’ clinical

2018 Asian Pacific journal of cancer prevention : APJCP PubMed abstract

106. The UK ROPE Study: efficacy and safety of prostate artery embolisation for benign prostatic hyperplasia. An observational study and propensity matched comparison with transurethral resection of the prostate. (Full text)

The UK ROPE Study: efficacy and safety of prostate artery embolisation for benign prostatic hyperplasia. An observational study and propensity matched comparison with transurethral resection of the prostate. To assess the efficacy and safety of prostate artery embolization (PAE) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and to conduct an indirect comparison of PAE with transurethral resection of the prostate (TURP).As a joint initiative between (...) the British Society of Interventional Radiologists, the British Association of Urological Surgeons and the National Institute for Health and Care Excellence, we conducted the UK Register of Prostate Embolization (UK-ROPE) study, which recruited 305 patients across 17 UK urological/interventional radiology centres, 216 of whom underwent PAE and 89 of whom underwent TURP. The primary outcomes were International Prostate Symptom Score (IPSS) improvement in the PAE group at 12 months post-procedure

2018 BJU international PubMed abstract

107. Comparison of &lt; 100 cc prostates and &gt; 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. (Abstract)

Comparison of < 100 cc prostates and > 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. Surgical options for benign prostatic hyperplasia (BPH) become limited when treating large prostates due to steep learning curves and less effective treatment. Aquablation (AquaBeam System, PROCEPT BioRobotics, Inc., USA) could remedy this. We compare the effectiveness of Aquablation in large prostates between 80 cc and 100 cc and very large prostates > 100 cc.WATER II (...) (NCT03123250) is a prospective, multicenter, international clinical trial of Aquablation for the surgical treatment of LUTS/BPH in men of age 45-80 years with prostates between 80 cc and 150 cc. Aquablation was performed using the AquaBeam System. The reported analysis compares the subgroup of patients with a baseline prostate size of < 100 cc versus those with a prostate size of > 100 cc. Students' t test was used for continuous variables and Fisher's test for ordinal/binary variables.Of 114 screened

2018 World journal of urology

108. Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial (Full text)

Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial Benign prostatic hyperplasia (BPH) is a prevalent disease associated with lower urinary tract symptoms (LUTS). The standard of care for moderate-to-severe LUTS unresponsive to pharmacological treatment is the transurethral resection of the prostate (TURP). However, this intervention is not exempt from complications (...) . Prostatic artery embolization (PAE) has been described as a new, effective and safe procedure for the treatment of LUTS secondary to BPH. To date, only one clinical trial has been published on the use of PAE for LUTS, but the study was methodologically flawed in terms of safety monitoring. Therefore, well-designed clinical studies are required to compare the efficacy and safety of both techniques in the treatment of LUTS secondary to BPH.This was a prospective, randomized, non-inferiority clinical trial

2018 Research and reports in urology Controlled trial quality: uncertain PubMed abstract

109. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia UroLift for treating lower urinary tr UroLift for treating lower urinary tract act symptoms of benign prostatic symptoms of benign prostatic h hyperplasia yperplasia Medical technologies guidance Published: 16 September 2015 nice.org.uk/guidance/mtg26 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 35Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 21 System impact 21 5 Cost considerations 23

2015 National Institute for Health and Clinical Excellence - Medical technologies

110. Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia

Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia TITLE: Dutasteride and Finasteride for Men with Benign Prostatic Hyperplasia: Comparative Clinical Effectiveness and Safety DATE: 07 March 2014 RESEARCH QUESTIONS 1. What is the comparative clinical effectiveness and safety of dutasteride and finasteride for men with benign prostatic hyperplasia? 2. What is the clinical effectiveness and safety of dutasteride versus placebo for men with benign prostatic hyperplasia? 3. What (...) is the clinical effectiveness and safety of finasteride versus placebo for men with benign prostatic hyperplasia? KEY MESSAGE Four systematic reviews and six randomized controlled trials were found regarding the clinical effectiveness and safety of dutasteride and finasteride compared to each other or placebo for the treatment of benign prostatic hyperplasia. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

111. Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis

Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

112. Non-drug interventions for the treatment of benign prostatic syndrome (BPS)

Non-drug interventions for the treatment of benign prostatic syndrome (BPS) 1 Translation of the key statement of the rapid report Nichtmedikamentöse lokale Verfahren zur Behandlung des benignen Prostatasyndroms – Aktualisierung (Version 1.1; Status: 2 August 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N15-07 Non (...) -drug local procedures for treatment of benign prostatic syndrome – update 1 Key statement of rapid report N15-07 Version 1.1 Non-drug local procedures for treatment of BPS – update 2 August 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Non-drug local procedures for treatment of benign prostatic syndrome – update Commissioning agency: Federal Joint Committee Commission awarded on: 25

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

113. Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. (Abstract)

Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. 29650236 2018 12 18 2018 12 18 1873-7560 74 2 2018 08 European urology Eur. Urol. Re: WATER: A Double-blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. 233 S0302-2838(18)30244-6 10.1016/j.eururo.2018.03.026 Madersbacher Stephan S Department of Urology, Kaiser Franz Josef (...) Hospital, Sigmund Freud Private University, Vienna, Austria. Electronic address: madersbacher@hotmail.com. eng Journal Article Comment 2018 04 09 Switzerland Eur Urol 7512719 0302-2838 059QF0KO0R Water IM J Urol. 2018 May;199(5):1252-1261 29360529 Double-Blind Method Humans Male Prostatic Hyperplasia surgery Transurethral Resection of Prostate Water 2018 03 03 2018 03 24 2018 4 14 6 0 2018 12 19 6 0 2018 4 14 6 0 ppublish 29650236 S0302-2838(18)30244-6 10.1016/j.eururo.2018.03.026

2018 European Urology Controlled trial quality: predicted high

114. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs. (Abstract)

Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs. Benign prostatic hyperplasia (BPH) is characterized by an enlargement of the prostate accompanied by an increase in prostatic blood perfusion and vascularization. The most indicated treatment is to perform orchiectomy, however, medical treatment with finasteride can be an option for breeding dogs or elderly animals with a critical health status. In dogs, the influence of medical treatment (...) on prostatic hemodynamics is still unknown. Therefore, this study aimed to evaluate the effects of benign prostatic hyperplasia and finasteride therapy on hemodynamic and vascular features of the canine prostate. For this purpose, twenty dogs of different breeds, body weights (10-30 kg) and ages (5-13 years) were used, assigned for: Healthy-non treated group (n = 5), BPH-non treated group (n = 5), Healthy-finasteride treated group (n = 5) and BPH-finasteride treated group (n = 5). Dogs that presented

2018 Theriogenology Controlled trial quality: uncertain

115. Randomized Controlled Trial of Aquablation vs. Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-Year Outcomes. (Abstract)

Randomized Controlled Trial of Aquablation vs. Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-Year Outcomes. To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) METHODS: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe (...) lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications.BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow

2018 Urology Controlled trial quality: predicted high

116. Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison. (Abstract)

Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison. Aim of our study is to compare the surgery outcomes and safety of button bipolar enucleation of the prostate vs. open prostatectomy in patients with large prostates (> 80 g) in a single-centre cohort study.All patients with lower urinary tract symptoms due to benign prostatic enlargement undergoing button bipolar enucleation of the prostate (B-TUEP) or open (...) prostatectomy (OP) between May 2012 and December 2013 were enroled in our study. Data on clinical history, physical examination, urinary symptoms, erectile function, uroflowmetry and prostate volume were collected at 0, 1, 3, 6, 12, 24 and 36 months. Early and long-term complications were recorded.Overall, 240 patients were enroled. Out of them 111 patients (46%) performed an OP and 129 patients (54%) performed a B-TUEP. In terms of efficacy, both procedures showed durable results at three years

2018 Prostate cancer and prostatic diseases

117. Impact of 5α-Reductase Inhibitors and α-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality. (Full text)

Impact of 5α-Reductase Inhibitors and α-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality. To investigate the use of 5α-reductase inhibitors (5ARIs) and α-blockers among men with benign prostatic hyperplasia (BPH) in relation to prostate cancer (PCa) incidence, severity and mortality.A retrospective 20-year cohort study in men residing in Saskatchewan, aged 40-89 years, with a BPH-coded medical claim between 1995 and 2014, was conducted. Cox proportional

2018 BJU international PubMed abstract

118. Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia. (Full text)

Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia. To assess changes in the rate of incidental prostate cancer (PCa) after benign prostatic hyperplasia (BPH) surgery over the last decade.We identified 1177 patients surgically treated for BPH (open prostatectomy, transurethral resection or holmium laser enucleation [HoLEP] of the prostate) in 2007-2016 at a single European academic center. Local polynomial regression was used to explore changes (...) in the rate of preoperative prostate biopsies (OR: 0.83; 95%CI: 0.79-0.88, P < .0001). Patients undergoing a preoperative biopsy showed a lower risk of being diagnosed with PCa after surgery (OR: 0.29; 95% CI: 0.12, 0.72 P = .007). Patients treated with HoLEP had a higher chance of incidental PCa detection (OR: 2.28; 95%CI: 1.30-4.00; P = .004), although this may be related to the significantly higher number of HoLEP performed over the last years.The increased rate of low-risk PCa detected after BPH

2018 Urology PubMed abstract

119. Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia (Full text)

Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia Oxidative stress is a primary cause of vascular endothelial damage. In the prostate, ischemia increases the levels of reactive oxygen species, growth factors and cytokines, and induces the development of angiogenesis, which results in cancer progression. The expression levels of an oxidative stress marker, 8-hydroxyguanosine (8-OHdG), were compared between prostate cancer (...) and non-neoplastic prostate tissues. A prostate tissue microarray composed of 10 cases of prostatic adenocarcinoma and 70 cases of benign prostatic hyperplasia was immunohistochemically stained for 8-OHdG. All cases expressed 8-OHdG. The levels of 8-OHdG expression in prostatic cancer (30.0% moderate and 70.0% strong) were significantly higher than those in benign prostatic hyperplasia (71.4% moderate and 28.6% strong; (p<0.01). Notably, 8-OHdG is expressed more highly in prostate cancer tissues

2018 Molecular and clinical oncology PubMed abstract

120. Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia (Full text)

Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia Intravesical prostatic protrusion (IPP) is a manifestation of benign prostatic hyperplasia marked by overgrowth of the prostatic median lobe into the bladder, producing bladder outlet obstruction and related storage and voiding symptoms.A MEDLINE® database search of the current literature was guided using combination of "prostate (...) " with the following terms: intravesical prostatic protrusion, bladder trabeculation, bladder outlet obstruction, lower urinary tract symptoms, alpha blockers, transrectal ultrasonography, and prostatectomy.Although IPP can be identified via a variety of imaging modalities, it is easily detected via transrectal ultrasonography (TRUS). Failing to detect IPP promptly by TRUS may result in refractory symptoms of benign prostatic hyperplasia, as the condition may not respond to typical α1-adrenoceptor antagonist

2018 Current urology PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>